You just read:

Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

News provided by

Regeneron Pharmaceuticals, Inc.

Aug 29, 2016, 02:00 ET